Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases

$112.71M USD

Funder	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Recipient Organization	Revagenix, Inc.
Country	United States
Start Date	Sep 22, 2022
End Date	Aug 31, 2025
Duration	1,074 days
Number of Grantees	1
Roles	Principal Investigator
Data Source	NIH (US)
Grant ID	`11047618`

Grant Description

To support the advanced development of candidate therapeutics for biodefense pathogens or emerging infectious diseases.

The supported research and development activities will progress the therapeutic product development and may include lead optimization, candidate selection, preclinical and IND enabling studies, Chemistry, Manufacturing, and Controls (CMC), IND submission, clinical safety and efficacy assessment.